Find trials
Search tips

A Study Of Digital Health Technologies For Detecting Cancer Treatment-Related Cardiotoxicities

Overview

About this study

The purpose of this study is to detect cardiotoxicity early in cancer patients using ML and wearables, potentially reducing CVD impact and improving long-term survival and quality of life.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18-80 years

  • Pre-transplant conditioning begun within approximately 30 days from the initial visit and having a post-transplant visit within approximately 100 days from transplantation.

Exclusion Criteria:

  • Inability to exercise

  • The presence of a left ventricular-assisted device or heart transplant

  • Currently taking beta blockers

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/16/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Courtney Wheatley-Guy, Ph.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20603712

Mayo Clinic Footer